Aptadir Therapeutics Closes €40 Million Seed Round
4BIO Capital leads a €40 million seed round in Aptadir Therapeutics to advance RNA inhibitor therapies, starting with lead candidate CAP1-FMR1 for Fragile X syndrome.
Topic
Rna Therapies
Topic
Topic
Topic
4BIO Capital leads a €40 million seed round in Aptadir Therapeutics to advance RNA inhibitor therapies, starting with lead candidate CAP1-FMR1 for Fragile X syndrome.